CO5690592A2 - 5-arilpirimidinas como agentes anticancer - Google Patents

5-arilpirimidinas como agentes anticancer

Info

Publication number
CO5690592A2
CO5690592A2 CO06038135A CO06038135A CO5690592A2 CO 5690592 A2 CO5690592 A2 CO 5690592A2 CO 06038135 A CO06038135 A CO 06038135A CO 06038135 A CO06038135 A CO 06038135A CO 5690592 A2 CO5690592 A2 CO 5690592A2
Authority
CO
Colombia
Prior art keywords
c3alkyl
groups
optionally substituted
c3alkanoyl
c3alkoxy
Prior art date
Application number
CO06038135A
Other languages
English (en)
Spanish (es)
Inventor
Nan Zhang
Kaloustian Semiramis Ayral
Thai Hiep Nguyen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CO5690592A2 publication Critical patent/CO5690592A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO06038135A 2003-09-24 2006-04-21 5-arilpirimidinas como agentes anticancer CO5690592A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50548703P 2003-09-24 2003-09-24

Publications (1)

Publication Number Publication Date
CO5690592A2 true CO5690592A2 (es) 2006-10-31

Family

ID=34393022

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06038135A CO5690592A2 (es) 2003-09-24 2006-04-21 5-arilpirimidinas como agentes anticancer

Country Status (24)

Country Link
US (1) US7524849B2 (https=)
EP (1) EP1663241B1 (https=)
JP (1) JP2007506746A (https=)
KR (1) KR20060089215A (https=)
CN (1) CN1871009A (https=)
AR (1) AR045811A1 (https=)
AT (1) ATE432077T1 (https=)
AU (1) AU2004275733A1 (https=)
BR (1) BRPI0414736A (https=)
CA (1) CA2539235A1 (https=)
CO (1) CO5690592A2 (https=)
DE (1) DE602004021269D1 (https=)
EC (1) ECSP066457A (https=)
GT (1) GT200400188A (https=)
IL (1) IL174305A0 (https=)
MX (1) MXPA06003207A (https=)
NO (1) NO20061319L (https=)
PA (1) PA8613201A1 (https=)
PE (1) PE20050470A1 (https=)
RU (1) RU2006107578A (https=)
SA (1) SA04250303A (https=)
TW (1) TW200512198A (https=)
WO (1) WO2005030216A1 (https=)
ZA (1) ZA200602386B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
MX2007015718A (es) * 2005-06-13 2008-02-21 Wyeth Corp Inhibidor de tubulina y proceso para su preparacion.
CN101193884A (zh) 2005-06-13 2008-06-04 惠氏公司 微管蛋白抑制剂和其制备方法
WO2007110418A2 (de) * 2006-03-27 2007-10-04 Basf Se Substituierte 5-hetaryl-4-aminopyrimidine
CL2007002231A1 (es) * 2006-08-02 2008-04-11 Basf Ag Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico.
TW200836741A (en) * 2007-01-11 2008-09-16 Basf Ag 2-substituted pyrimidines I in therapy
WO2009007187A1 (de) * 2007-07-09 2009-01-15 Basf Se Substituierte 5-hetarylpyrimidine
US9139534B2 (en) 2011-04-22 2015-09-22 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
US9649317B2 (en) 2012-09-19 2017-05-16 The Trustees Of The University Of Pennsylvania Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
CN107108524A (zh) 2014-12-16 2017-08-29 西格诺药品有限公司 2‑(叔丁基氨基)‑4‑((1r,3r,4r)‑3‑羟基‑4‑甲基环己基氨基)‑嘧啶‑5‑甲酰胺的配制物
US9513297B2 (en) 2014-12-16 2016-12-06 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CN107922287B (zh) 2015-07-24 2021-04-09 细胞基因公司 合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体
US11623927B2 (en) 2018-03-02 2023-04-11 The Trustees Of The University Of Pennsylvania Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules
EP4052759A4 (en) * 2019-11-01 2023-12-20 Unimatec Co., Ltd. FLUORINE-CONTAINING PYRIMIDINE COMPOUND AND METHOD FOR THE PRODUCTION THEREOF
TW202132285A (zh) * 2019-11-13 2021-09-01 美商愛彼特生物製藥股份有限公司 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US116429A (en) * 1871-06-27 Improvement in dial-telegraph apparatus
US61889A (en) * 1867-02-05 Improvement in animal teaps
US69242A (en) * 1867-09-24 Calvin pepper
US88096A (en) * 1869-03-23 t h a y e r
US147744A (en) * 1874-02-24 Improvement in locomotive-furnaces
GB9700664D0 (en) 1997-01-14 1997-03-05 British Tech Group Anti-cancer agents
US6117876A (en) * 1997-04-14 2000-09-12 American Cyanamid Company Fungicidal trifluorophenyl-triazolopyrimidines
DE69934224T2 (de) 1998-04-27 2007-10-04 Kumiai Chemical Industry Co., Ltd. 3-arylphenylsulfid-derivate und insektizide und mitizide
US6156925A (en) * 1998-09-25 2000-12-05 American Cyanamid Company Process for the preparation of halogenated phenylmaloates
US5986135A (en) * 1998-09-25 1999-11-16 American Cyanamid Company Fungicidal trifluoromethylalkylamino-triazolopyrimidines
JP2004503542A (ja) * 2000-06-13 2004-02-05 ビーエーエスエフ アクチェンゲゼルシャフト 殺真菌性5−フェニル置換2−(シアノアミノ)ピリミジン誘導体
US6670362B2 (en) * 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
EA007719B1 (ru) * 2001-03-15 2006-12-29 Басф Акциенгезельшафт 5-фенилпиримидины, способ и промежуточные продукты для их получения и их применение для борьбы с фитопатогенными грибами
ES2242839T3 (es) * 2001-04-20 2005-11-16 Ciba Specialty Chemicals Holding Inc. 4-amino-2- (piridin-2-il)pirimidina como sustancias activas microbicidas.
NZ533265A (en) 2001-11-19 2006-05-26 Basf Ag 5-Phenylpyrimidines, their preparation, compositions comprising them and their use
US7320975B2 (en) 2002-02-21 2008-01-22 Basf Aktiengesellschaft 2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, method and intermediate products for the production and use thereof for combating noxious fungi
US7731985B2 (en) 2002-03-15 2010-06-08 Ciba Specialty Chemicals Corporation 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
EA013811B1 (ru) 2002-11-21 2010-08-30 Новартис Вэксинес Энд Дайэгностикс, Инк. 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака

Also Published As

Publication number Publication date
NO20061319L (no) 2006-04-20
EP1663241B1 (en) 2009-05-27
JP2007506746A (ja) 2007-03-22
GT200400188A (es) 2005-05-02
KR20060089215A (ko) 2006-08-08
DE602004021269D1 (de) 2009-07-09
PA8613201A1 (es) 2005-11-25
AU2004275733A1 (en) 2005-04-07
SA04250303A (ar) 2005-12-03
US20050075357A1 (en) 2005-04-07
MXPA06003207A (es) 2006-06-23
AR045811A1 (es) 2005-11-16
CA2539235A1 (en) 2005-04-07
RU2006107578A (ru) 2007-10-27
US7524849B2 (en) 2009-04-28
CN1871009A (zh) 2006-11-29
TW200512198A (en) 2005-04-01
ZA200602386B (en) 2009-03-25
BRPI0414736A (pt) 2006-11-21
IL174305A0 (en) 2008-02-09
ECSP066457A (es) 2006-09-18
ATE432077T1 (de) 2009-06-15
EP1663241A1 (en) 2006-06-07
PE20050470A1 (es) 2005-10-03
WO2005030216A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
CO5690592A2 (es) 5-arilpirimidinas como agentes anticancer
RU2009117642A (ru) Применение спирооксиндоловых соединений в качестве терапевтических средств
AR120338A1 (es) Piridazinonas como inhibidores de parp7
RU2015143841A (ru) Ингибиторы hdac
RU2487124C2 (ru) Новое амидное производное и его использование в качестве лекарственного средства
BRPI0508966A (pt) composto, composição farmacêutica, e, uso de um composto
AR064106A1 (es) Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
AR077849A2 (es) Compuestos y composiciones como inhibidores de proteina quinasa
TW200718422A (en) 1,6-Dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
AR046201A1 (es) Metodos para preparar derivados 7-(beta-d-ribofuranosilo sustituido en 2'-r1)-4(nr2r3)-5-(etin-1-ilo sustituido)- pirrol[2,3- d]pirimidina
CY1111834T1 (el) Παραγωγα της 4-(2-αμινο-1-hydroxyethyl)phenol σαν αγωνιστικa του αδρενεργικου (adrenergic) ληπτη βητα -2
JP2008535902A5 (https=)
AR082201A1 (es) Bencenosulfonamidas utiles como inhibidores del canal de sodio
AR074024A1 (es) Compuesto de arilazol-2-il-cianoetilamino enantiomericamente enriquecidos, composicion plaguicida y su uso para prevenir la infeccion parasitaria
GEP20084488B (en) Use of therapeutic agents for treating pain
DE60101000D1 (de) N-heterocyclische derivate als nos inhibitoren
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
DE60024471D1 (de) Benzopyran derivate
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
EA200401455A1 (ru) Производные бензоксазина в качестве модуляторов 5-htи их применение
MY136824A (en) Substituted benzoxazinones and uses thereof
AR057408A1 (es) Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
CO5690598A2 (es) 6-[(sustituido)fenil]triazolopirimidinas como agentes anticancer

Legal Events

Date Code Title Description
FC Application refused